Mutz, Julian http://orcid.org/0000-0001-5308-1957
Wong, Win Lee Edwin
Powell, Timothy R.
Young, Allan H.
Dawe, Gavin S.
Lewis, Cathryn M.
Funding for this research was provided by:
NIHR Maudsley Biomedical Research Centre
Article History
Received: 15 January 2024
Accepted: 17 March 2024
First Online: 28 March 2024
Declarations
:
: Ethical approval for the UK Biobank study has been granted by the National Information Governance Board for Health and Social Care and the NHS North West Multicentre Research Ethics Committee (11/NW/0382). No project-specific ethical approval is needed.
: AHY declares the following: paid lectures and advisory boards for companies with drugs used in affective and related disorders (Flow Neuroscience, Novartis, Roche, Janssen, Takeda, Noema pharma, Compass, Astrazenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, Sage and Neurocentrx); principal investigator in the Restore-Life VNS registry study funded by LivaNova; principal investigator on “ESKETINTRD3004: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression”; principal investigator on “The Effects of Psilocybin on Cognitive Function in Healthy Participants”; principal investigator on “The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)”; principal investigator on “A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy” (Janssen); principal investigator on “An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants with Major Depressive Disorder (MDD)” (Janssen); principal investigator on “A Randomized, Double-blind, Multicentre, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy”; principal investigator on “A Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients with Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNR” (Janssen); UK chief investigator for Compass COMP006 & COMP007 studies; UK chief investigator for Novartis MDD study MIJ821A12201; grant funding (past and present) from NIMH (USA), CIHR (Canada), NARSAD (USA), Stanley Medical Research Institute (USA), MRC (UK), Wellcome Trust (UK), Royal College of Physicians (Edin), BMA (UK), UBC-VGH Foundation (Canada), WEDC (Canada), CCS Depression Research Fund (Canada), MSFHR (Canada), NIHR (UK), Janssen (UK) and EU Horizon 2020. No shareholdings in pharmaceutical companies. CML sits on the scientific advisory board for Myriad Neuroscience and has received speaker fees from SYNLAB and consultancy fees from UCB. JM, WLEW, TRP and GSD declare no financial conflict of interest.